By Kelly Cloonan
Shares of BriaCell Therapeutics climbed after the company said its late stage breast cancer treatment outperformed leading antibody-drug conjugates for some patients in its Phase 2 study.
The stock rose 16% to $4.34 on Wednesday. Shares have declined 87% over the past 12 months.
The biotechnology company said its Bria-IMT plus check point inhibitors showed a 17.3-month survival rate for patients with hormone receptor-positive breast cancer, exceeding the 14.4 months of Trodelvy, the current ADC standard of care.
For patients with triple negative breast cancer, the survival data for the treatment was similar to that of Trodelvy but higher than that of chemotherapy, the company said.
Patients with hormone receptor-positive and triple negative breast cancer represent a significant proportion of the patient population, yet are the most difficult groups to treat, Chief Medical Officer Dr. Giuseppe Del Priore said.
The Phase 2 data shows Bria-IMT has the potential to provide an effective and well-tolerated therapeutic option for those patient groups, Del Priore said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 16, 2025 13:32 ET (17:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。